Cargando…
Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus
Goals of investigation: The 5-year survival rate for pancreatic ductal adenocarcinoma (PDAC) has remained at <5% for decades because no effective therapies have been identified. Integrin αvβ6 is overexpressed in most PDAC and represents a promising therapeutic target. Thus, we attempted to develo...
Autores principales: | Moore, Kate M., Desai, Ami, Delgado, Bea de Luxán, Trabulo, Sara Maria David, Reader, Claire, Brown, Nicholas F., Murray, Elizabeth R., Brentnall, Adam, Howard, Philip, Masterson, Luke, Zammarchi, Francesca, Hartley, John A., van Berkel, Patrick H., Marshall, John F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7053198/ https://www.ncbi.nlm.nih.gov/pubmed/32194845 http://dx.doi.org/10.7150/thno.38702 |
Ejemplares similares
-
Examination of soluble integrin resistant mutants of foot-and-mouth disease virus
por: Lawrence, Paul, et al.
Publicado: (2013) -
The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy
por: Reader, Claire S, et al.
Publicado: (2019) -
Rules of engagement between αvβ6 integrin and foot-and-mouth disease virus
por: Kotecha, Abhay, et al.
Publicado: (2017) -
Foot & mouth disease
Publicado: (2006) -
Foot and Mouth Disease
Publicado: (1884)